Spots Global Cancer Trial Database for A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
Official Title: A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Study ID: NCT01025206
Conditions
Interventions
Study Description
Brief Summary: This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program, Salt Lake City, Utah, United States
AZ Sint-Jan, Brugge, , Belgium
Ghent University Hospital, Ghent, , Belgium
Rigshospitalet, Copenhagen, , Denmark
Karolinska University Hospital, Huddinge, , Sweden
Hematology Clinic Cancer Division, Skåne University Hospital, Lund, , Sweden
Contact Details
Name: Guido Tricot, MD, PhD, Prof.
Affiliation: University of Utah
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
